Wednesday, October 14, 2026

Less Than Six Hours Before The Market Open, Riot Blockchain Is Up By 4%

ViaNews Editorial Team

February 16, 2023

Less Than Six Hours Before The Market Open, Riot Blockchain Is Up By 4%

(VIANEWS) - The NASDAQ opens in less than six hours and Riot Blockchain's pre-market value is already 4.95% up.

Riot Blockchain's last close was $6.66, 71.85% below its 52-week high of $23.66.

The last session, NASDAQ ended with Riot Blockchain (RIOT) rising 12.88% to $6.66. NASDAQ jumped 0.92% to $12,070.59, after three consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session.

About Riot Blockchain

Riot Blockchain, Inc., together with its subsidiaries, focuses on bitcoin mining operations in North America. It operates through Bitcoin Mining, Data Center Hosting, and Electrical Products and Engineering segments. As of December 31, 2021, it operated approximately 30,907 miners. Riot Blockchain, Inc. was incorporated in 2000 and is headquartered in Castle Rock, Colorado.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.3.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -36.5%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 87.5% and 95.2%, respectively.

Sales Growth

Riot Blockchain's sales growth for the next quarter is negative 5.6%.

Moving Average

Riot Blockchain's value is way higher than its 50-day moving average of $4.85 and higher than its 200-day moving average of $6.40.

More news about Riot Blockchain (RIOT).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com